Broadcom named strategic vendor for Walmart virtualization solutions
CAMBRIDGE, MA—Edward H. Myles, the Chief Operating Officer and Chief Financial Officer of Scholar Rock Holding Corp (NASDAQ:SRRK), recently reported significant stock transactions. According to a Form 4 filing with the Securities and Exchange Commission, Myles sold shares totaling approximately $5.07 million on March 10, 2025. The shares were sold at prices ranging from $34.87 to $35.82. The transaction comes as Scholar Rock, now valued at $3.39 billion, has seen its stock surge over 330% in the past six months, according to InvestingPro data.
In addition to the sales, Myles also acquired shares through various stock option exercises. The total value of these acquisitions amounted to approximately $1.54 million, with prices ranging from $4.86 to $18.08 per share. Following these transactions, Myles holds a total of 111,345 restricted stock units, reflecting his ongoing investment in the company.
These transactions were completed under a pre-established Rule 10b5-1 trading plan, adopted on November 19, 2024.
In other recent news, Scholar Rock Holding Corp. reported a significant earnings miss for the fourth quarter of 2024, with actual earnings per share (EPS) of -$2.47 compared to an analyst forecast of -$0.58. Despite this miss, the company’s stock rose in premarket trading, reflecting investor optimism about upcoming product launches and strategic developments. Scholar Rock is focusing on launching its SMA treatment, Apetigramab, in the U.S. by the fourth quarter of 2025, and in the EU by 2026. The company is also planning to file an Investigational New Drug (IND) application for SRK-439, targeting the cardiometabolic market, in the third quarter of 2025.
These recent developments are seen as drivers for future revenue growth and competitive positioning. Analysts from firms such as Piper Sandler and Jefferies have shown interest in the company’s strategic focus on broadening its therapeutic reach, particularly in neuromuscular indications. Scholar Rock’s emphasis on expanding its neuromuscular franchise and exploring new indications is aligned with industry trends toward innovative, targeted therapies. The company is also engaging with payers to ensure market readiness for its upcoming launches, underscoring its commitment to addressing unmet medical needs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.